{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:52:49Z","timestamp":1790704369617,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Opioids are the mainstay of cancer-related pain management but are limited by adverse effects and clinical complexity. Cannabinoids have been proposed as adjunctive, opioid-sparing agents, yet their impact on opioid consumption in cancer patients remains uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This systematic review and meta-analysis was conducted according to PRISMA 2020 guidelines and registered in PROSPERO (CRD420251175971). Randomized and nonrandomized clinical studies involving adult cancer patients receiving opioids for pain and treated with cannabinoids were included. Outcomes comprised total opioid consumption, maintenance\/background opioid dose, and breakthrough\/rescue opioid use. Placebo-controlled comparisons were analyzed separately from within-group baseline changes. Risk of bias was assessed using RoB 2 and ROBINS-I, and certainty of evidence using GRADE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifteen studies met inclusion criteria, with ten eligible for meta-analysis. Placebo-controlled analyses showed no significant differences between cannabinoids and placebo for total, maintenance, or breakthrough opioid use. Baseline-change analyses demonstrated heterogeneous and formulation-dependent effects, with modest reductions in maintenance opioid dose observed primarily in THC-predominant regimens, driven by isolated studies. Overall certainty of evidence was low due to heterogeneity and methodological limitations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Cannabinoids are not associated with consistent or clinically meaningful opioid-sparing effects in cancer pain under controlled conditions. Observed benefits in uncontrolled analyses are variable and not reliably reproduced. Cannabinoids should not be considered a dependable opioid-sparing strategy in cancer pain management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00520-026-10856-y","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T03:16:26Z","timestamp":1780974986000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cannabinoids and opioid consumption in cancer pain: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"34","author":[{"given":"Ioana","family":"Creang\u0103-Murariu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teodora","family":"Alexa-Stratulat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matei Ioan","family":"Rusu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Chiru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camelia","family":"Dascalu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina-Elena","family":"Dobre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan-Ionel","family":"Tamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"10856_CR1","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3390\/CANCERS15030591\/S1","volume":"15","author":"RAH Snijders","year":"2023","unstructured":"Snijders RAH, Brom L, Theunissen M, van den Beuken-van Everdingen MHJ (2023) Update on prevalence of pain in patients with cancer 2022: a systematic literature review and meta-analysis. Cancers (Basel) 15:591. https:\/\/doi.org\/10.3390\/CANCERS15030591\/S1","journal-title":"Cancers (Basel)"},{"key":"10856_CR2","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1097\/J.PAIN.0000000000001242","volume":"159","author":"SV Pasricha","year":"2018","unstructured":"Pasricha SV, Tadrous M, Khuu W, Juurlink DN, Mamdani MM, Michael Paterson J, Gomes T (2018) Clinical indications associated with opioid initiation for pain management in Ontario, Canada: a population-based cohort study. Pain 159:1562\u20131568. https:\/\/doi.org\/10.1097\/J.PAIN.0000000000001242","journal-title":"Pain"},{"key":"10856_CR3","doi-asserted-by":"crossref","unstructured":"Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, Glaser SE, Vallejo R (2008) Opioid complications and side effects. Pain Physician 11(2Suppl):S105\u2013S120","DOI":"10.36076\/ppj.2008\/11\/S105"},{"key":"10856_CR4","doi-asserted-by":"publisher","unstructured":"Lewis CES, Schutzer-Weissmann J, Farquhar-Smith P (2023) Opioid use disorder in cancer patients. https:\/\/doi.org\/10.1097\/SPC.0000000000000640","DOI":"10.1097\/SPC.0000000000000640"},{"key":"10856_CR5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/978-3-662-46450-2_7","volume":"227","author":"SG Woodhams","year":"2015","unstructured":"Woodhams SG, Sagar DR, Burston JJ, Chapman V (2015) The role of the endocannabinoid system in pain. Handb Exp Pharmacol 227:119\u2013143. https:\/\/doi.org\/10.1007\/978-3-662-46450-2_7","journal-title":"Handb Exp Pharmacol"},{"key":"10856_CR6","doi-asserted-by":"publisher","unstructured":"Kendall DA, Yudowski GA (2017) Cannabinoid receptors in the central nervous system: their signaling and roles in disease. Front Cell Neurosci 10:294, 294. https:\/\/doi.org\/10.3389\/FNCEL.2016.00294","DOI":"10.3389\/FNCEL.2016.00294"},{"key":"10856_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/J.NEUROSCIENCE.2013.04.034","volume":"248","author":"JL Scavone","year":"2013","unstructured":"Scavone JL, Sterling RC, Van Bockstaele EJ (2013) Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal. Neuroscience 248:637. https:\/\/doi.org\/10.1016\/J.NEUROSCIENCE.2013.04.034","journal-title":"Neuroscience"},{"key":"10856_CR8","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1007\/S11912-025-01695-X","volume":"27","author":"I Creang\u0103-Murariu","year":"2025","unstructured":"Creang\u0103-Murariu I, Rezu\u0219 II, Karami R, Rancz A, Zolcs\u00e1k \u00c1, Engh MA, Obeidat M, Tamba BI, Hegyi P, Bunduc S (2025) Indications of cannabinoids for the palliation of cancer-associated symptoms: a systematic review and meta-analysis. Curr Oncol Rep 27:1080\u20131096. https:\/\/doi.org\/10.1007\/S11912-025-01695-X","journal-title":"Curr Oncol Rep"},{"key":"10856_CR9","doi-asserted-by":"publisher","unstructured":"H\u00e4user W, Welsch P, Radbruch L, Fisher E, Bell RF, Moore RA (2023) Cannabis-Based Medicines and Medical Cannabis for Adults with Cancer Pain. Cochrane Database Syst Rev 6. https:\/\/doi.org\/10.1002\/14651858.CD014915.PUB2","DOI":"10.1002\/14651858.CD014915.PUB2"},{"key":"10856_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/BMJOPEN-2020-047717","volume":"11","author":"A Noori","year":"2021","unstructured":"Noori A, Miroshnychenko A, Shergill Y, Ashoorion V, Rehman Y, Couban RJ, Buckley ND, Thabane L, Bhandari M, Guyatt Gea, Buckley DN et al (2021) Opioid-sparing effects of medical cannabis or cannabinoids for chronic pain: a systematic review and meta-analysis of randomised and observational studies. BMJ Open 11:e047717. https:\/\/doi.org\/10.1136\/BMJOPEN-2020-047717","journal-title":"BMJ Open"},{"key":"10856_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/BMJ.N71","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. https:\/\/doi.org\/10.1136\/BMJ.N71","journal-title":"BMJ"},{"key":"10856_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.ED000142","volume":"10","author":"M Cumpston","year":"2019","unstructured":"Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, Thomas J (2019) Updated guidance for trusted systematic reviews: a new edition of the Cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev 10:ED000142. https:\/\/doi.org\/10.1002\/14651858.ED000142","journal-title":"Cochrane Database Syst Rev"},{"key":"10856_CR13","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1002\/JRSM.1563","volume":"13","author":"NR Haddaway","year":"2022","unstructured":"Haddaway NR, Grainger MJ, Gray CT (2022) Citationchaser: a tool for transparent and efficient forward and backward citation chasing in systematic searching. Res Synth Methods 13:533\u2013545. https:\/\/doi.org\/10.1002\/JRSM.1563","journal-title":"Res Synth Methods"},{"key":"10856_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/S13643-016-0384-4","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan-a web and mobile app for systematic reviews. Syst Rev. https:\/\/doi.org\/10.1186\/S13643-016-0384-4","journal-title":"Syst Rev"},{"key":"10856_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/BMJ.L4898","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. https:\/\/doi.org\/10.1136\/BMJ.L4898","journal-title":"BMJ"},{"key":"10856_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/BMJ.I4919","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. https:\/\/doi.org\/10.1136\/BMJ.I4919","journal-title":"BMJ"},{"key":"10856_CR17","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/J.JCLINEPI.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y, Glasziou P, Debeer H (2011) GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64:383\u2013394. https:\/\/doi.org\/10.1016\/J.JCLINEPI.2010.04.026","journal-title":"J Clin Epidemiol"},{"key":"10856_CR18","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/SIM.1186","volume":"21","author":"JPT Higgins","year":"2002","unstructured":"Higgins JPT, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539\u20131558. https:\/\/doi.org\/10.1002\/SIM.1186","journal-title":"Stat Med"},{"key":"10856_CR19","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jpainsymman.2009.06.008","volume":"39","author":"JR Johnson","year":"2010","unstructured":"Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fallon MT (2010) Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J Pain Symptom Manage 39:167\u2013179. https:\/\/doi.org\/10.1016\/j.jpainsymman.2009.06.008","journal-title":"J Pain Symptom Manage"},{"key":"10856_CR20","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jpain.2012.01.003","volume":"13","author":"RK Portenoy","year":"2012","unstructured":"Portenoy RK, Ganae-Motan ED, Allende S, Yanagihara R, Shaiova L, Weinstein S, McQuade R, Wright S, Fallon MT (2012) Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain 13:438\u2013449. https:\/\/doi.org\/10.1016\/j.jpain.2012.01.003","journal-title":"J Pain"},{"key":"10856_CR21","doi-asserted-by":"publisher","first-page":"iv166","DOI":"10.1093\/ANNONC\/MDY152","volume":"29","author":"M Fallon","year":"2018","unstructured":"Fallon M, Giusti R, Aielli F, Hoskin P, Rolke R, Sharma M, Ripamonti CI (2018) Management of cancer pain in adult patients: ESMO clinical practice guidelines. Ann Oncol 29:iv166\u2013iv191. https:\/\/doi.org\/10.1093\/ANNONC\/MDY152","journal-title":"Ann Oncol"},{"key":"10856_CR22","doi-asserted-by":"publisher","unstructured":"Hardy JR, Greer RM, Pelecanos AM, Huggett GE, Kearney AM, Gurgenci TH, Good PD (2025) Medicinal cannabis for symptom control in advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of 1:1 tetrahydrocannabinol and cannabidiol. Support Care Cancer 33:1. https:\/\/doi.org\/10.1007\/S00520-025-09763-5","DOI":"10.1007\/S00520-025-09763-5"},{"key":"10856_CR23","doi-asserted-by":"publisher","unstructured":"Hardy J, Haywood A, Gogna G, Martin J, Yates P, Greer R, Good P (2020) Oral medicinal cannabinoids to relieve symptom burden in the palliative care of patients with advanced cancer: a double-blind, placebo-controlled, randomised clinical trial of efficacy and safety of 1:1 Delta-9-Tetrahydrocannabinol (THC) and Cannabidiol \u2026. Trials 21. https:\/\/doi.org\/10.1186\/S13063-020-04541-6","DOI":"10.1186\/S13063-020-04541-6"},{"key":"10856_CR24","doi-asserted-by":"publisher","unstructured":"Zylla DM, Eklund J, Gilmore G, Gavenda A, Guggisberg J, VazquezBenitez G, Pawloski PA, Arneson T, Richter S, Birnbaum Aea et al (2021) A randomized trial of medical cannabis in patients with Stage IV cancers to assess feasibility, dose requirements, impact on pain and opioid use, safety, and overall patient satisfaction. Support Care Cancer 29:7471\u20137478. https:\/\/doi.org\/10.1007\/S00520-021-06301-X","DOI":"10.1007\/S00520-021-06301-X"},{"key":"10856_CR25","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jpainsymman.2017.09.001","volume":"55","author":"AH Lichtman","year":"2018","unstructured":"Lichtman AH, Lux EA, McQuade R, Rossetti S, Sanchez R, Sun W, Wright S, Kornyeyeva E, Fallon MT (2018) Results of a double-blind, randomized, placebo-controlled study of Nabiximols oromucosal spray as an adjunctive therapy in advanced cancer patients with chronic uncontrolled pain. J Pain Symptom Manage 55:179\u2013188. https:\/\/doi.org\/10.1016\/j.jpainsymman.2017.09.001","journal-title":"J Pain Symptom Manage"},{"key":"10856_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0270543","volume":"17","author":"S Clarke","year":"2022","unstructured":"Clarke S, Butcher BE, McLachlan AJ, Henson JD, Rutolo D, Hall S, Vitetta L (2022) Pilot clinical and pharmacokinetic study of \u03949-Tetrahydrocannabinol (THC)\/Cannabidiol (CBD) nanoparticle oro-buccal spray in patients with advanced cancer experiencing uncontrolled pain. PLoS ONE 17:e0270543. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0270543","journal-title":"PLoS ONE"},{"key":"10856_CR27","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1089\/JPM.2019.0540","volume":"23","author":"PD Good","year":"2020","unstructured":"Good PD, Greer RM, Huggett GE, Hardy JR (2020) An open-label pilot study testing the feasibility of assessing total symptom burden in trials of cannabinoid medications in palliative care. J Palliat Med 23:650\u2013655. https:\/\/doi.org\/10.1089\/JPM.2019.0540","journal-title":"J Palliat Med"},{"key":"10856_CR28","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/J.JAPH.2019.10.013","volume":"60","author":"ER Pritchard","year":"2020","unstructured":"Pritchard ER, Dayer L, Belz J, Forseth B, Harrington SE, Painter JT (2020) Effect of cannabis on opioid use in patients with cancer receiving palliative care. J Am Pharm Assoc (2003) 60:244\u2013247. https:\/\/doi.org\/10.1016\/J.JAPH.2019.10.013","journal-title":"J Am Pharm Assoc (2003)"},{"key":"10856_CR29","doi-asserted-by":"publisher","first-page":"E1285","DOI":"10.1136\/SPCARE-2022-004003","volume":"13","author":"S Aprikian","year":"2024","unstructured":"Aprikian S, Kasvis P, Vigano ML, Hachem Y, Canac-Marquis M, Vigano A (2024) Medical cannabis is effective for cancer-related pain: Quebec Cannabis Registry results. BMJ Support Palliat Care 13:E1285\u2013E1291. https:\/\/doi.org\/10.1136\/SPCARE-2022-004003","journal-title":"BMJ Support Palliat Care"},{"key":"10856_CR30","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/BCPT.13660","volume":"130","author":"JG Bramness","year":"2022","unstructured":"Bramness JG, Hjellvik V, Stubhaug A, Skurtveit S (2022) Possible opioid-saving effect of cannabis-based medicine using individual-based data from the Norwegian prescription database. Basic Clin Pharmacol Toxicol 130:84\u201392. https:\/\/doi.org\/10.1111\/BCPT.13660","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10856_CR31","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1089\/JPM.2019.0374","volume":"23","author":"IM Pawasarat","year":"2020","unstructured":"Pawasarat IM, Schultz EM, Frisby JC, Mehta S, Angelo MA, Hardy SS, Kim TWB (2020) The efficacy of medical marijuana in the treatment of cancer-related pain. J Palliat Med 23:809\u2013816. https:\/\/doi.org\/10.1089\/JPM.2019.0374","journal-title":"J Palliat Med"},{"key":"10856_CR32","doi-asserted-by":"publisher","unstructured":"Sura KT, Kohman L, Huang D, Pasniciuc SV (2022) Experience with medical marijuana for cancer patients in the palliative setting. Cureus 14.\u00a0https:\/\/doi.org\/10.7759\/CUREUS.26406","DOI":"10.7759\/CUREUS.26406"},{"key":"10856_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2020.100667","author":"EM Webster","year":"2020","unstructured":"Webster EM, Yadav GS, Gysler S, McNamara B, Black J, Tymon-Rosario J, Zeybek B, Han C, Arkfeld CK, Andikyan Vea et al (2020) Prescribed medical cannabis in women with gynecologic malignancies: a single-institution survey-based study. Gynecol Oncol Rep. https:\/\/doi.org\/10.1016\/j.gore.2020.100667","journal-title":"Gynecol Oncol Rep"},{"key":"10856_CR34","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1177\/2049463717710042","volume":"11","author":"MT Fallon","year":"2017","unstructured":"Fallon MT, Albert Lux E, McQuade R, Rossetti S, Sanchez R, Sun W, Wright S, Lichtman AH, Kornyeyeva E (2017) Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: Two double-blind, randomized, placebo-controlled Phase 3 studies. Br J Pain 11:119\u2013133. https:\/\/doi.org\/10.1177\/2049463717710042","journal-title":"Br J Pain"},{"key":"10856_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/J.PNPBP.2020.110065","volume":"106","author":"B Le Foll","year":"2021","unstructured":"Le Foll B (2021) Opioid-sparing effects of cannabinoids: Myth or reality? Prog Neuropsychopharmacol Biol Psychiatry 106:110065. https:\/\/doi.org\/10.1016\/J.PNPBP.2020.110065","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10856_CR36","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/J.JPAIN.2021.05.008","volume":"22","author":"CJ Hayes","year":"2021","unstructured":"Hayes CJ, Krebs EE, Brown J, Li C, Hudson T, Martin BC (2021) Association between pain intensity and discontinuing opioid therapy or transitioning to intermittent opioid therapy after initial long-term opioid therapy: a retrospective cohort study. J Pain 22:1709\u20131721. https:\/\/doi.org\/10.1016\/J.JPAIN.2021.05.008","journal-title":"J Pain"},{"key":"10856_CR37","doi-asserted-by":"publisher","DOI":"10.1093\/CDN\/NZAA152","volume":"4","author":"KM Cochrane","year":"2020","unstructured":"Cochrane KM, Williams BA, Fischer JAJ, Samson KLI, Pei LX, Karakochuk CD (2020) Regression to the mean: a statistical phenomenon of worthy consideration in anemia research. Curr Dev Nutr 4:nzaa152. https:\/\/doi.org\/10.1093\/CDN\/NZAA152","journal-title":"Curr Dev Nutr"},{"issue":"2","key":"10856_CR38","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/S00406-024-01880-2","volume":"275","author":"E Hoch","year":"2024","unstructured":"Hoch E, Volkow ND, Friemel CM, Lorenzetti V, Freeman TP, Hall W (2024) Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits. Eur Arch Psychiatry Clin Neurosci 275(2):281\u2013292. https:\/\/doi.org\/10.1007\/S00406-024-01880-2","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"1","key":"10856_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-23079-8","volume":"15","author":"MJ Geum","year":"2025","unstructured":"Geum MJ, Yoo SH, Lee SW, Hong M, Jung EH, Kim YJ, Kang B (2025) Impact of CNS medication burden and drug interactions on delirium in patients with advanced cancer: a multicenter prospective observational study. Sci Rep 15(1):39425-. https:\/\/doi.org\/10.1038\/s41598-025-23079-8","journal-title":"Sci Rep"},{"key":"10856_CR40","unstructured":"(2018) WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents. World Health Organisation"},{"key":"10856_CR41","doi-asserted-by":"publisher","unstructured":"Creang\u0103-Murariu I, Froicu EM, Scripcariu DV, Bacoanu G, Poroch M, Moscalu M, Tarniceriu CC, Alexa-Stratulat T, Poroch V (2025) Timing matters: a systematic review of early versus delayed palliative care in advanced cancer. Cancers (Basel) 17. https:\/\/doi.org\/10.3390\/CANCERS17152598\/S1","DOI":"10.3390\/CANCERS17152598\/S1"},{"key":"10856_CR42","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/S41386-022-01322-4","volume":"47","author":"S Nielsen","year":"2022","unstructured":"Nielsen S, Picco L, Murnion B, Winters B, Matheson J, Graham M, Campbell G, Parvaresh L, Khor KE, Betz-Stablein Bea et al (2022) Opioid-sparing effect of cannabinoids for analgesia: an updated systematic review and meta-analysis of preclinical and clinical studies. Neuropsychopharmacology 47:1315\u20131330. https:\/\/doi.org\/10.1038\/S41386-022-01322-4","journal-title":"Neuropsychopharmacology"},{"key":"10856_CR43","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1097\/J.PAIN.0000000000002283","volume":"162","author":"JS Gewandter","year":"2021","unstructured":"Gewandter JS, Smith SM, Dworkin RH, Turk DC, Gan TJ, Gilron I, Hertz S, Katz NP, Markman JD, Raja Sea et al (2021) Research approaches for evaluating opioid sparing in clinical trials of acute and chronic pain treatments: initiative on methods, measurement, and pain assessment in clinical trials recommendations. Pain 162:2669. https:\/\/doi.org\/10.1097\/J.PAIN.0000000000002283","journal-title":"Pain"},{"key":"10856_CR44","doi-asserted-by":"publisher","first-page":"849","DOI":"10.71480\/NMJ.V66I5.592","volume":"66","author":"OA Omokore","year":"2025","unstructured":"Omokore OA, Quadri IO, Kingdom PJ, Ogbuiyi-Chima IC, Meribole SE, Olayinka TO, Ogunnoiki S, Precious S-O, Olaitan A, Chima-Ogbuiyi N et al (2025) Opioids in Cancer Pain Management: A Double-Edged Sword of Relief and Risk. Niger Med J 66:849. https:\/\/doi.org\/10.71480\/NMJ.V66I5.592","journal-title":"Niger Med J"},{"key":"10856_CR45","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1016\/J.PAIN.2011.01.040","volume":"152","author":"P Klepstad","year":"2011","unstructured":"Klepstad P, Fladvad T, Skorpen F, Bjordal K, Caraceni A, Dale O, Davies A, Kloke M, Lundstr\u00f6m S, Maltoni Mea et al (2011) Influence from genetic variability on opioid use for cancer pain: a European genetic association study of 2294 cancer pain patients. Pain 152:1139\u20131145. https:\/\/doi.org\/10.1016\/J.PAIN.2011.01.040","journal-title":"Pain"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10856-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-10856-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10856-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T18:02:32Z","timestamp":1784052152000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-10856-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10856"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-10856-y","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]},"assertion":[{"value":"14 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No ethical approval was required for this systematic review with meta-analysis, as all data were already published in peer-reviewed journals. No patients were involved in the design, conduct or interpretation of our study.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"633"}}